問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林永國

Recruiting

List

5Cases

2025-07-01 - 2030-12-31

Active
A phase III, randomized, double-blind, placebo-controlled, parallel-group trial was conducted to evaluate the efficacy of AZD0780 in patients with established atherosclerotic cardiovascular disease (ASCVD) or at high risk of first ASCVD events for major adverse cardiovascular events.

  • Condition/Disease

    Patients with established atherosclerotic cardiovascular disease or at high risk of their first atherosclerotic cardiovascular event.

  • Test Drug

    AZD0780

Participate Sites
23Sites

Recruiting23Sites

2025-03-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Recruiting18Sites

2023-04-13 - 2027-05-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2023-03-01 - 2027-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2022-12-05 - 2024-09-30

Phase III

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack

  • Test Drug

    AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)

Participate Sites
23Sites

Not yet recruiting2Sites

Recruiting20Sites

Terminated1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB